Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
Earnings Data
Report Date
Jul 01, 2025TBA Not Confirmed
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.1Last Year’s EPS
0.11Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 05, 2025
|% Change Since: -20.05%
|Next Earnings Date:Jul 01, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, successful FDA approval of GRAFAPEX, and strategic equity offering. However, challenges such as declining IXINITY demand, regulatory issues with terbinafine, and upcoming generic competition for Rupall present obstacles.Company Guidance
During the Medexus Pharmaceuticals Third Quarter 2025 Conference Call, several key financial metrics were highlighted, reflecting the company's robust performance and strategic initiatives. The company reported a fiscal Q3 2025 revenue of $30 million, up from $25.2 million the previous year, and an adjusted EBITDA of $5.8 million, an increase from $3.2 million in the same period last year, resulting in an adjusted EBITDA margin of over 19%. Net income for the quarter was $0.7 million, marking a $1.2 million improvement over the previous year's net loss. Cash flow from operations was strong, with quarterly operating cash flow reaching $6.7 million. The company completed a CAD30 million public offering, which bolstered its financial position, anticipating the commercial launch of GRAFAPEX in the U.S. by April 2025. Additionally, Medexus acknowledged a $15 million regulatory milestone payment obligation to its partner Medac, following GRAFAPEX's FDA approval. The company also reported varied performance across its product lines, with notable growth in Trecondyv unit demand in Canada and Gleolan in the U.S., while IXINITY faced a slight demand decrease. Medexus remains focused on leveraging its financial discipline and product portfolio to sustain growth and capitalize on upcoming market opportunities.Successful FDA Approval and Upcoming Launch of GRAFAPEX
GRAFAPEX received FDA approval and holds Orphan Drug Designation, offering at least seven years of exclusivity in the U.S. The company is preparing for a commercial launch with expectations of product availability by April 2025 and potential annual revenue exceeding $100 million within five years.
Positive Financial Performance in Fiscal Q3 2025
Revenue increased to $30 million from $25.2 million in the same period last year. Adjusted EBITDA rose to $5.8 million from $3.2 million, and net income improved to $0.7 million from a loss of $0.5 million. Operating income increased to $3.8 million from $1.6 million.
Strong Cash Position and Successful Equity Offering
Completion of a CAD30 million public offering with net proceeds of approximately $19.7 million USD, enhancing the balance sheet and de-risking financial obligations.
Growth in Rupall and Gleolan Demand
Rupall unit demand in Canada increased by 18%, and Gleolan unit demand in the U.S. grew by 8% over the trailing 12-month period.
---
TSE:MDP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSE:MDP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 05, 2025 | C$3.79 | C$3.05 | -19.53% |
| Nov 07, 2024 | C$2.20 | C$2.17 | -1.36% |
| Aug 07, 2024 | C$2.27 | C$2.46 | +8.37% |
| Jun 25, 2024 | C$1.69 | C$1.72 | +1.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Medexus Pharmaceuticals Inc (TSE:MDP) report earnings?
Medexus Pharmaceuticals Inc (TSE:MDP) is schdueled to report earning on Jul 01, 2025, TBA Not Confirmed.
What is Medexus Pharmaceuticals Inc (TSE:MDP) earnings time?
Medexus Pharmaceuticals Inc (TSE:MDP) earnings time is at Jul 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:MDP EPS forecast?
TSE:MDP EPS forecast for the fiscal quarter 2025 (Q4) is -0.1.
---